7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE
Key Takeaways
- The 'A-OK' pharmacotherapeutic protocol is an emergency multi-drug regimen comprising Atropine (1 mg IV) for vagolysis and bradycardia prevention, Ondansetron (8 mg IV) for 5-HT3 receptor blockade to blunt serotonin-mediated pulmonary vasospasm and vagal reflexes, and Ketorolac (30 mg IV) to inhibit cyclooxygenase and block thromboxane A2-mediated pulmonary vasoconstriction and platelet aggregation.
- Hemodynamic resuscitation in AFE requires an RV-protective strategy: Norepinephrine is the first-line vasopressor to restore systemic vascular resistance and right coronary perfusion pressure without excessively increasing pulmonary vascular resistance; inotropes (Epinephrine, Dobutamine, Milrinone) and selective pulmonary vasodilators (inhaled epoprostenol or inhaled nitric oxide) optimize RV output, while excessive crystalloid fluids (>500-1000 mL) must be strictly avoided to prevent RV volume overload and worsening septal bowing.
- Coagulopathy in AFE is characterized by hyperacute consumption of fibrinogen and fulminant secondary hyperfibrinolysis; immediate activation of the Massive Transfusion Protocol (1:1:1 balanced ratio) with aggressive early administration of Cryoprecipitate (target fibrinogen >=150-200 mg/dL; 10-20 units) and Tranexamic Acid (1 g IV over 10 minutes within 3 hours) is life-saving.
- Point-of-Care viscoelastic testing (TEG or ROTEM) provides rapid, real-time guidance for targeted blood component therapy in AFE-induced DIC, specifically detecting severe hypofibrinogenemia (decreased alpha angle and low TEG MA or ROTEM FIBTEM A10/A20) and rapid clot lysis (elevated LY30 or ROTEM ML).
- Refractory cardiopulmonary collapse in AFE unresponsive to conventional inotropes and mechanical ventilation warrants immediate evaluation for Extracorporeal Membrane Oxygenation (ECMO): Veno-Arterial (VA-ECMO) for severe biventricular or RV failure and cardiogenic shock, and Veno-Venous (VV-ECMO) for isolated refractory ARDS with preserved cardiac function.
Last updated: August 2026
A-OK Protocol, Hemodynamic Support & Critical Care in AFE
The management of Amniotic Fluid Embolism (AFE) represents one of the greatest challenges in obstetric critical care. Survival requires immediate, aggressive, multi-professional intervention targeting three simultaneous physiological crises: acute right ventricular failure with pulmonary hypertension, left ventricular pump failure with ARDS, and fulminant consumptive coagulopathy (DIC) with massive hemorrhage.
1. Immediate Cardiopulmonary Resuscitation & Emergency Mobilization
Upon clinical suspicion of AFE, emergency mobilization must occur instantaneously without waiting for laboratory or diagnostic confirmation:
+---------------------------------------------------------------------------------------------------+
| IMMEDIATE RESUSCITATION MOBILIZATION CHECKLIST |
| |
| 1. ACTIVATE CODE BLUE & OBSTETRIC CODE TEAM: |
| • Mobilize Maternal Code Team, Obstetric Anesthesiology, Critical Care / Intensivist, |
| Obstetric Surgery, Blood Bank, and Neonatal Resuscitation Program (NRP) team. |
| |
| 2. AIRWAY & VENTILATION (100% FiO2): |
| • Immediate endotracheal intubation by the most experienced provider using video laryngoscopy.|
| • Use a smaller cuffed ETT (size 6.0 to 7.0 mm) due to airway edema. |
| • Apply lung-protective mechanical ventilation (Low tidal volume 6 mL/kg PBW, PEEP 8-12 cmH2O)|
| to maintain PaO2 >60 mmHg (SpO2 >=92-95%) while avoiding excessive intrathoracic pressure. |
| |
| 3. CONTINUOUS MANUAL LEFT UTERINE DISPLACEMENT (LUD): |
| • If pregnant >=20 weeks (fundus at/above umbilicus), maintain continuous manual LUD on a |
| flat backboard. Establish vascular access strictly ABOVE the diaphragm. |
| |
| 4. PERIMORTEM CESAREAN DELIVERY (PMCD / RESUSCITATIVE HYSTEROTOMY): |
| • If maternal cardiac arrest does not achieve ROSC within 4 minutes, INITIATE PMCD at 4 min |
| with delivery by 5 minutes at the bedside. Emptying the uterus relieves IVC occlusion. |
| |
| 5. ACTIVATE MASSIVE TRANSFUSION PROTOCOL (MTP) STAT: |
| • Request uncrossed O-negative/type-specific blood, FFP, platelets, cryoprecipitate, and TXA. |
+---------------------------------------------------------------------------------------------------+
2. The "A-OK" Protocol: Mechanisms, Pharmacology & Clinical Administration
Introduced into clinical practice by Clark, Rezai, and colleagues, the "A-OK" regimen is a novel, multi-drug pharmacotherapeutic bundle designed to directly counteract the acute immune, autonomic, and pro-inflammatory cascades of AFE.
+---------------------------------------------------------------------------------------------------+
| THE "A-OK" PHARMACOTHERAPY REGIMEN |
| |
| A • ATROPINE: 1.0 mg IV Push |
| - Mechanism: Muscarinic receptor antagonist (vagolysis). |
| - Target: Blocks severe vagal-mediated bradycardia, blunts the Bezold-Jarisch reflex, |
| prevents vagally induced coronary and pulmonary arteriolar constriction. |
| |
| O • ONDANSETRON: 8.0 mg IV Push |
| - Mechanism: Highly selective 5-HT3 (serotonin) receptor antagonist. |
| - Target: Blocks serotonin released by degranulating platelets/mast cells; prevents |
| serotonin-mediated pulmonary vasoconstriction, bronchospasm, and vagal bradycardia. |
| |
| K • KETOROLAC: 30.0 mg IV Push (15 mg if renal impairment / elderly) |
| - Mechanism: Non-selective Cyclooxygenase (COX-1 and COX-2) inhibitor. |
| - Target: Blocks arachidonic acid conversion into Thromboxane A2 (TXA2) and prostaglandins; |
| suppresses downstream microvascular thrombosis and intense pulmonary vasoconstriction. |
+---------------------------------------------------------------------------------------------------+
Clinical Rationale & Timing of A-OK Administration
- Immediate Administration: The A-OK regimen should be administered as early as possible—ideally at the first clinical suspicion of AFE or immediately following ROSC during active CPR.
- Safety Profile: Given the catastrophic lethality of unmitigated AFE, the potential benefit of blunting pulmonary vasoconstriction and right ventricular collapse far outweighs the minimal transient side effects of these three agents.
- Ketorolac & Coagulopathy Concern: Clinicians frequently ask whether ketorolac (an NSAID with antiplatelet effects) is safe in the setting of impending DIC. In AFE, the primary driver of death is acute right ventricular failure and cardiogenic shock; ketorolac's inhibition of thromboxane A2-mediated pulmonary vasospasm and microvascular clotting is therapeutic, and a single 30 mg dose does not worsen systemic coagulopathic hemorrhage.
3. Hemodynamic Support & Right Ventricular-Protective Strategy
Resuscitating the failing right ventricle in AFE requires strict adherence to RV-protective hemodynamic principles:
+---------------------------------------------------------------------------------------------------+
| RIGHT VENTRICLE (RV) RESUSCITATION PRINCIPLES IN AFE |
| |
| 1. AVOID FLUID OVERLOAD (Strict Fluid Restriction): |
| • The acutely failing RV is overstretched and operating on the descending limb of Starling's |
| curve. Large crystalloid boluses (>500-1000 mL) worsen RV dilation, increase tricuspid |
| regurgitation, exacerbate leftward septal shift (D-sign), and reduce LV output! |
| • Maintain euvolemia; restrict maintenance crystalloids and replace volume primarily with |
| blood products during hemorrhage. |
| |
| 2. RESTORE SYSTEMIC ARTERIAL PRESSURE (Aortic Root Pressure): |
| • The right coronary artery (RCA) perfuses the RV myocardium during both systole and diastole.|
| • When SBP drops below RV systolic pressure, the RV becomes profoundly ischemic and arrests. |
| • Maintain MAP >=65-70 mmHg aggressively using vasopressors to ensure RCA perfusion. |
| |
| 3. SELECTIVE PULMONARY VASODILATION: |
| • Deliver inhaled pulmonary vasodilators directly to ventilated alveoli to drop PVR without |
| causing systemic hypotension. |
+---------------------------------------------------------------------------------------------------+
Vasoactive & Inotropic Drug Selection in AFE
| Medication | Receptor Targets | Typical Dosing Range | Clinical Role & Hemodynamic Impact in AFE |
|---|---|---|---|
| Norepinephrine | Alpha-1 >> Beta-1 | 0.05 to 0.5 mcg/kg/min IV infusion | First-line vasopressor. Potent alpha-1 vasoconstriction restores SVR and aortic root pressure, driving right coronary perfusion without significantly increasing pulmonary vascular resistance (PVR). Beta-1 activity supports RV contractility. |
| Vasopressin | V1 receptors | 0.03 to 0.04 units/min IV fixed rate | Second-line vasopressor. Causes systemic vasoconstriction while sparing or even dilating the pulmonary vasculature via endothelial nitric oxide release; significantly lowers the PVR-to-SVR ratio. |
| Epinephrine | Beta-1 = Beta-2 > Alpha-1 (low dose); Alpha-1 (high dose) | 0.02 to 0.2 mcg/kg/min IV infusion (or 1 mg IV in arrest) | Inotrope / vasopressor of choice in cardiac arrest or severe biventricular shock. Provides powerful inotropic, chronotropic, and bronchodilatory support. |
| Milrinone | PDE-3 Inhibitor | 0.25 to 0.75 mcg/kg/min IV (omit bolus) | Inodilator. Increases RV and LV myocardial contractility while decreasing PVR and pulmonary artery pressures. Must be paired with Norepinephrine to prevent systemic hypotension. |
| Inhaled Epoprostenol (Flolan) / Inhaled Nitric Oxide (iNO) | Direct pulmonary vascular smooth muscle relaxation | Epoprostenol: 10–50 ng/kg/min;<br/>iNO: 20–40 ppm | Selective pulmonary vasodilators. Reduces RV afterload and improves V/Q matching without causing systemic hypotension or reducing SVR. |
4. Advanced Mechanical Circulatory Support (ECLS & ECMO)
When severe right ventricular failure, cardiogenic shock, or hypoxemia proves refractory to maximal pharmacotherapy and mechanical ventilation, Extracorporeal Life Support (ECLS) is life-saving:
+---------------------------------------------------------------------------------------------------+
| ECMO MODALITIES IN REFRACTORY AFE RESUSCITATION |
| |
| 1. VENO-ARTERIAL ECMO (VA-ECMO) — CARDIAC & RESPIRATORY SUPPORT: |
| • Primary Indication: Refractory cardiogenic shock, severe RV failure, biventricular collapse,|
| or Extracorporeal CPR (E-CPR) during prolonged cardiac arrest. |
| • Cannulation: Deoxygenated blood is drained from the right atrium/femoral vein, pumped |
| through an external membrane oxygenator, and returned under pressure into the femoral or |
| axillary artery to perfuse the systemic circulation. |
| • Hemodynamic Effect: Immediately unloads the failing right ventricle, restores full systemic |
| perfusion, and provides complete gas exchange while the myocardium recovers. |
| |
| 2. VENO-VENOUS ECMO (VV-ECMO) — RESPIRATORY SUPPORT ONLY: |
| • Primary Indication: Refractory hypoxemic respiratory failure / severe ARDS (PaO2/FiO2 <80) |
| where cardiac contractility and RV/LV function remain intact. |
| • Cannulation: Blood drained from femoral vein, oxygenated, and returned to internal jugular. |
| |
| 3. RIGHT VENTRICULAR ASSIST DEVICE (RVAD / Impella RP): |
| • Percutaneous catheter pump delivering blood from the IVC/RA directly into the pulmonary |
| artery, bypassing the failing RV to maintain forward pulmonary blood flow. |
+---------------------------------------------------------------------------------------------------+
ECMO ANTICOAGULATION PEARL: In patients with active AFE-induced DIC, standard therapeutic heparin infusions during ECMO cannulation must be withheld or significantly reduced until surgical and coagulopathic hemostasis is achieved. Modern heparin-bonded circuits permit heparin-free ECMO runs for 24 to 48 hours.
5. Consumptive Coagulopathy & Viscoelastic-Guided Massive Transfusion
Fulminant consumptive coagulopathy occurs in up to 80% of AFE patients, driven by the catastrophic discharge of procoagulant tissue factor and secondary hyperfibrinolysis.
Blood Component Resuscitation Strategy
- Massive Transfusion Protocol (MTP): Initiate balanced transfusion in a 1:1:1 ratio (Packed Red Blood Cells : Fresh Frozen Plasma : Platelets).
- Target Physiological Endpoints:
- Fibrinogen >=150 to 200 mg/dL (The single most vital parameter in obstetric coagulopathy!).
- Platelet count >=50,000 to 100,000/uL.
- Hemoglobin >=8 g/dL (Hematocrit >25%).
- Prothrombin Time (PT/INR) <=1.5; aPTT <=1.5x control.
- Ionized Calcium >=1.1 to 1.3 mmol/L (Administer 1 to 2 g Calcium Gluconate IV for every 2 to 4 units of PRBCs transfused to treat citrate toxicity).
- Core temperature >=36.0°C and arterial pH >7.20.
+---------------------------------------------------------------------------------------------------+
| HEMOSTATIC PHARMACOTHERAPY IN AFE-INDUCED DIC |
| |
| 1. CRYOPRECIPITATE (FIRST-LINE FIBRINOGEN REPLACEMENT): |
| • Dose: **10 to 20 units (1 to 2 pools) IV stat**; repeat based on laboratory levels. |
| • Impact: Each 10-unit pool provides ~2 to 3 g of fibrinogen, raising serum fibrinogen by |
| 50 to 100 mg/dL. Also replenishes Factor VIII, Factor XIII, and von Willebrand factor. |
| |
| 2. FIBRINOGEN CONCENTRATE (RiaSTAP / Fibryga): |
| • Dose: **2 to 4 g IV push** (dosed at 30 to 60 mg/kg). |
| • Advantages: Lyophilized, reconstitutes in minutes, no thawing delay, no ABO type match |
| required, and delivers high fibrinogen in very low volume (avoids volume overload). |
| |
| 3. TRANEXAMIC ACID (TXA — ANTIFIBRINOLYTIC): |
| • Dose: **1 g IV infused over 10 minutes**, administered as early as possible within 3 hours. |
| • Repeat Dose: A second dose of 1 g IV if bleeding continues after 30 minutes. |
| • Mechanism: Competitive inhibitor of plasminogen activation; halts rapid clot breakdown. |
+---------------------------------------------------------------------------------------------------+
Point-of-Care Viscoelastic Hemostatic Testing (TEG & ROTEM)
Standard coagulation tests (PT, INR, aPTT, fibrinogen) require 45 to 60 minutes for laboratory turnaround—far too slow during hyperacute AFE collapse. Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) provide real-time, dynamic evaluation of clot formation, strength, and lysis within 10 to 15 minutes:
| Viscoelastic Parameter | TEG Value | ROTEM Value | Clinical Interpretation | Targeted Hemotherapy Action |
|---|---|---|---|---|
| Clotting Initiation | R-time (>10 min) | CT (>240 sec) | Severe clotting factor deficiency | Transfuse Fresh Frozen Plasma (FFP) or 4-Factor PCC |
| Clot Kinetics / Fibrin Dynamics | Alpha Angle (<53°) | Alpha Angle (<60°) | Fibrinogen deficiency / impaired fibrin cross-linking | Transfuse Cryoprecipitate (10–20 units) or Fibrinogen Concentrate |
| Clot Strength | MA (<50 mm) | MCF (<50 mm) | Platelet deficiency OR severe hypofibrinogenemia | If FIBTEM is normal, transfuse Platelets (1 apheresis unit) |
| Functional Fibrinogen Clot | Functional Fibrinogen MA (<10 mm) | FIBTEM A10 / A20 (<10 mm) | Critical hypofibrinogenemia (isolated from platelets) | Administer Cryoprecipitate or Fibrinogen Concentrate STAT |
| Clot Lysis (Hyperfibrinolysis) | LY30 (>3%) | ML (>15%) | Fulminant hyperfibrinolysis (rapid clot breakdown) | Administer Tranexamic Acid (TXA 1 g IV) immediately |
6. Surgical & Obstetric Hemostasis Strategies
Torrential postpartum uterine hemorrhage is a hallmark of Phase 2 AFE. When medical management fails, surgical escalation must proceed systematically:
+---------------------------------------------------------------------------------------------------+
| STEPWISE SURGICAL & MECHANICAL HEMOSTASIS IN AFE |
| |
| 1. UTEROTONICS & BIMANUAL COMPRESSION: |
| • Oxytocin infusion (30-40 units in 1L saline), Methylergonovine 0.2 mg IM (avoid if severe |
| hypertension/vasospasm), Carboprost (Hemabate) 0.25 mg IM (CAUTION: Carboprost can cause |
| intense bronchospasm and increase pulmonary artery pressure—use with extreme caution in AFE!)|
| |
| 2. INTRAUTERINE BALLOON TAMPONADE: |
| • Insert Bakri Balloon inflated with 300 to 500 mL warm sterile saline. |
| • Provides mechanical compression against bleeding myometrial venous sinusoids. |
| |
| 3. SURGICAL COMPRESSION SUTURES & VASCULAR LIGATION: |
| • B-Lynch or Hayman uterine compression sutures. |
| • Bilateral uterine artery ligation (O'Leary stitches) or internal iliac (hypogastric) |
| artery ligation. |
| |
| 4. EMERGENT TOTAL / SUBTOTAL HYSTERECTOMY: |
| • Definitive surgical therapy if bleeding persists. Do not delay hysterectomy until the |
| patient develops irreversible shock and profound hypothermia. |
| |
| 5. DAMAGE CONTROL SURGERY & PELVIC PACKING: |
| • If diffuse microvascular oozing persists despite hysterectomy due to severe DIC: |
| - Pack the pelvis firmly with laparotomy sponges. |
| - Leave fascia open with negative pressure temporary abdominal closure (ABThera/wound vac). |
| - Transfer to ICU to correct the 'lethal triad' (acidosis, hypothermia, coagulopathy). |
| - Planned re-exploration in 24 to 48 hours for pack removal. |
+---------------------------------------------------------------------------------------------------+
Loading diagram...
Test Your Knowledge
A 31-year-old G2P1 at 38 weeks of gestation experiences sudden cardiovascular collapse and profound hypoxemia immediately following delivery. The obstetric team suspects Amniotic Fluid Embolism. The critical care team decides to administer the 'A-OK' pharmacotherapeutic regimen. Which of the following drug combinations, dosages, and mechanisms correctly describes this protocol?
A
B
C
D
Test Your Knowledge
A 35-year-old patient with AFE-induced acute cor pulmonale is intubated and mechanically ventilated in the ICU. Bedside echocardiogram reveals severe right ventricular enlargement, moderate tricuspid regurgitation, and leftward shifting of the interventricular septum. Blood pressure is 74/42 mmHg. Which hemodynamic management strategy is most appropriate?
A
B
C
D
Test Your Knowledge
A 28-year-old postpartum patient with AFE develops torrential uterine bleeding. Point-of-care ROTEM demonstrates a prolonged clotting time (CT), a severely reduced FIBTEM A10 of 4 mm (reference >10 mm), and a Maximum Lysis (ML) of 32% (reference <15%). Laboratory results return confirming a serum fibrinogen of 65 mg/dL. In addition to PRBCs and FFP, which therapeutic interventions are most urgently indicated?
A
B
C
D
Test Your Knowledge
A 32-year-old patient who survived the initial arrest phase of AFE remains in profound cardiogenic shock with a cardiac index of 1.4 L/min/m2, severe biventricular dysfunction, and persistent arterial hypotension despite maximal infusions of norepinephrine, epinephrine, and inhaled epoprostenol. Which advanced critical care intervention is most appropriate at this stage?
A
B
C
D